Frank Rimerman Advisors LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

Frank Rimerman Advisors LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 77.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,122 shares of the biopharmaceutical company’s stock after selling 75,752 shares during the period. Frank Rimerman Advisors LLC’s holdings in Pfizer were worth $587,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Van Strum & Towne Inc. boosted its holdings in shares of Pfizer by 5.5% in the fourth quarter. Van Strum & Towne Inc. now owns 69,684 shares of the biopharmaceutical company’s stock valued at $1,849,000 after acquiring an additional 3,655 shares in the last quarter. Brandes Investment Partners LP boosted its holdings in Pfizer by 16.8% during the fourth quarter. Brandes Investment Partners LP now owns 6,708,164 shares of the biopharmaceutical company’s stock worth $177,968,000 after buying an additional 962,837 shares in the last quarter. Zevin Asset Management LLC boosted its holdings in Pfizer by 46.0% during the fourth quarter. Zevin Asset Management LLC now owns 16,182 shares of the biopharmaceutical company’s stock worth $429,000 after buying an additional 5,095 shares in the last quarter. Hills Bank & Trust Co boosted its holdings in Pfizer by 1.9% during the fourth quarter. Hills Bank & Trust Co now owns 71,214 shares of the biopharmaceutical company’s stock worth $1,889,000 after buying an additional 1,339 shares in the last quarter. Finally, Greatmark Investment Partners Inc. purchased a new stake in Pfizer during the fourth quarter worth about $230,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $25.74 on Monday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a 50 day moving average price of $26.24 and a 200 day moving average price of $27.12. The firm has a market capitalization of $145.85 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 earnings per share. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.